BridgeBio Oncology Therapeutics, Inc. Increase (Decrease) in Accounts Payable
BridgeBio Oncology Therapeutics, Inc. (BBOT) reported Increase (Decrease) in Accounts Payable of $5.36 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-11
- BridgeBio Oncology Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$5.33M.
- BridgeBio Oncology Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $10.69M, a 1889.76% increase year-over-year.
- BridgeBio Oncology Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$2.42M, a 223.63% decline year-over-year.
- BridgeBio Oncology Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $2.09M.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$5.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $5.36M 10-Q · filed 2026-08-11 | $2.94M derived: sum of 3 quarters · filed 2026-08-11 | $5.03M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $10.69M 10-Q · filed 2026-05-12 | $8.27M derived: sum of 2 quarters · filed 2026-05-12 | $10.36M derived: sum of 3 quarters · filed 2026-05-12 | $8.31M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$2.42M derived: POS AM 12 month − 10-Q 9 month · filed 2026-04-30 | -$326.00K derived: sum of 2 quarters · filed 2026-04-30 | -$2.38M derived: sum of 3 quarters · filed 2026-08-11 | -$1.84M POS AM · filed 2026-04-30 |
| 2025-09-30 | $2.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $40.00K derived: sum of 2 quarters · filed 2026-08-11 | $577.00K 10-Q · filed 2025-11-12 | $2.53M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$2.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$1.51M 10-Q · filed 2026-08-11 | $441.00K derived: sum of 3 quarters · filed 2026-08-11 | |
| 2025-03-31 | $537.00K 10-Q · filed 2026-05-12 | $2.49M derived: sum of 2 quarters · filed 2026-05-12 | ||
| 2024-12-31 | $1.96M derived: POS AM 12 month − 10-Q 9 month · filed 2026-04-30 | $2.50M POS AM · filed 2026-04-30 | ||
| 2024-09-30 | $543.00K 10-Q · filed 2025-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |